18:04 , Oct 25, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Tumor-penetrating nanoparticles could be used to deliver chemotherapy and phototherapy for cancer. The nanoparticles are comprised of the photosensitizer sinoporphyrin sodium, which produces reactive oxygen species in response to red light irradiation; ferric...
20:34 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Adcetris meets in Phase III for first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin plus chemotherapy met the primary and all key secondary endpoints in the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Pheophorbide A-based micelle nanoparticles could be used to deliver chemotherapy, photothermal therapy and photodynamic therapy for cancer. The micelle nanoparticles are composed of the hydrophobic photosensitizer pheophorbide A, conjugated to hydrophilic chemotherapies via...
16:22 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
19:21 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Photothermal-activated nanoparticles could be used for sequential delivery of chemotherapy and photothermal therapy for cancer. The nanoparticles consist of an inner porous silica shell containing a palladium (II)-based photothermal agent which emits heat...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports updated Phase Ib/II data for ovarian cancer candidate

ImmunoGen Inc. (NASDAQ:IMGN) reported updated data from the Phase Ib/II FORWARD II trial evaluating mirvetuximab soravtansine (IMGN853) to treat folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer. The data were released in an abstract...
15:22 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest inhibiting BARD1, BRCA1, CDK1 or CKD12 could help treat tamoxifen-resistant breast cancer. In tumor tissue from 27 recurrent breast cancer patients whose tumors became resistant...
21:53 , Apr 17, 2018 |  BC Extra  |  Politics & Policy

Australia to evaluate Lilly's Lartruvo under new provisional pathway

Australia's Therapeutic Goods Administration (TGA) said soft tissue sarcoma drug Lartruvo olaratumab from Eli Lilly and Co. (NYSE:LLY) was granted provisional approval determination, making the drug eligible for review under the country's new provisional approval...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...